Incidence of cancer in patients with ulcerative colitis 30 years after diagnosis (the IBSEN study)

References

• Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372(15):1441–1452. doi: 10.1056/NEJMra1403718.
   PubMed Web of Science ®Google Scholar
• Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9(11):945–965. doi: 10.1093/ecco-jcc/jjv141.
   PubMed Web of Science ®Google Scholar
• Lo B, Zhao M, Vind I, et al. The risk of extra-intestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2021;19(6):1117–1138.e19. doi: 10.1016/j.cgh.2020.08.015.
   Google Scholar
• Jussila A, Virta LJ, Pukkala E, et al. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol. 2013;48(12):1405–1413. doi: 10.3109/00365521.2013.846402.
   PubMed Web of Science ®Google Scholar
• Olen O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020;395(10218):123–131. doi: 10.1016/S0140-6736(19)32545-0.
   PubMed Web of Science ®Google Scholar
• Burisch J, Lophaven S, Munkholm P, et al. Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort. Aliment Pharmacol Ther. 2022;55(3):339–349. doi: 10.1111/apt.16677.
   PubMed Web of Science ®Google Scholar
• Adami HO, Bretthauer M, Emilsson L, et al. The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut. 2016;65(6):889–893. doi: 10.1136/gutjnl-2015-311003.
   PubMed Web of Science ®Google Scholar
• Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22(20):4794–4801. doi: 10.3748/wjg.v22.i20.4794.
   PubMed Web of Science ®Google Scholar
• Trivedi PJ, Crothers H, Mytton J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology. 2020;159(3):915–928. doi: 10.1053/j.gastro.2020.05.049.
   PubMed Web of Science ®Google Scholar
• Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (III). J Crohns Colitis. 2014;8(1):31–44. doi: 10.1016/j.crohns.2013.04.006.
   PubMed Web of Science ®Google Scholar
• Lirhus SS, Hoivik ML, Moum B, et al. Incidence and prevalence of inflammatory bowel disease in Norway and the impact of different case definitions: a nationwide registry study. Clin Epidemiol. 2021;13:287–294. doi: 10.2147/CLEP.S303797.
   PubMed Web of Science ®Google Scholar
• Yu J, Refsum E, Perrin V, et al. Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel. Ann Oncol. 2022;33(6):649–656. doi: 10.1016/j.annonc.2022.02.226.
   PubMed Web of Science ®Google Scholar
• Hovde O, Hoivik ML, Henriksen M, et al. Malignancies in patients with inflammatory bowel disease: results from 20 years of follow-up in the IBSEN study. J Crohns Colitis. 2017;11(5):571–577.
   PubMed Web of Science ®Google Scholar
• Moum B, Ekbom A, Vatn MH, et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in South Eastern Norway. Gut. 1997;40(3):328–332. doi: 10.1136/gut.40.3.328.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44(4):431–440. doi: 10.1080/00365520802600961.
   PubMed Web of Science ®Google Scholar
• Monstad IL, Solberg IC, Cvancarova M, et al. Outcome of ulcerative colitis 20 years after diagnosis in a prospective population-based inception cohort from South-Eastern Norway, the IBSEN study. J Crohns Colitis. 2021;15(6):969–979. doi: 10.1093/ecco-jcc/jjaa232.
   PubMed Web of Science ®Google Scholar
• Klepp P, Kisiel JB, Smastuen MC, et al. Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study. Scand J Gastroenterol. 2018;53(3):273–278. doi: 10.1080/00365521.2018.1424935.
   PubMed Web of Science ®Google Scholar
• Lunder AK, Hov JR, Borthne A, et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology. 2016;151(4):660–669 e4. doi: 10.1053/j.gastro.2016.06.021.
   PubMed Web of Science ®Google Scholar
• Adamo M, Groves C, Dickie L, et al. SEER Program Coding and Staging Manual 2023. National Institutes of Health National Cancer Institute; 2022.
   Google Scholar
• Cancer registry of Norway statistics bank [Internet]. Accessed 1 June 2022. Available from https://sb.kreftregisteret.no/.
   Google Scholar
• Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12(2):265–273 e1. doi: 10.1016/j.cgh.2013.03.034.
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi: 10.1136/gutjnl-2015-310912.
   PubMed Web of Science ®Google Scholar
• Follin-Arbelet B, Småstuen MC, Hovde Ø, et al. Mortality in patients with inflammatory bowel disease: results from 30 years of follow-up in a Norwegian inception cohort (the IBSEN study). J Crohns Colitis. 2023;17(4):497–503. doi: 10.1093/ecco-jcc/jjac156.
   PubMed Web of Science ®Google Scholar
• Bye WA, Nguyen TM, Parker CE, et al. Strategies for detecting colon cancer in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2017;9(9):CD000279.
   PubMed Web of Science ®Google Scholar
• Clarke WT, Feuerstein JD. Colorectal cancer surveillance in inflammatory bowel disease: practice guidelines and recent developments. World J Gastroenterol. 2019; 25(30):4148–4157. doi: 10.3748/wjg.v25.i30.4148.
   PubMed Web of Science ®Google Scholar
• Nasjonalt kvalitetsregister for tykk- og endetarmskreft, Årsrapport 2020. [Norwegian colorectal cancer registry, annual report 2020]. Cancer registry of Norway; 2021.
   Google Scholar
• Lundberg FE, Birgisson H, Johannesen TB, et al. Survival trends in patients diagnosed with Colon and rectal cancer in the nordic countries 1990-2016: the NORDCAN survival studies. Eur J Cancer. 2022;172:76–84. doi: 10.1016/j.ejca.2022.05.032.
   PubMed Web of Science ®Google Scholar
• Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014; 39(7):645–659. doi: 10.1111/apt.12651.
   PubMed Web of Science ®Google Scholar
• Bergquist A, Weismuller TJ, Levy C, et al. Impact on follow-up strategies in patients with primary sclerosing cholangitis. Liver Int. 2023;43(1):127–138. doi: 10.1111/liv.15286.
   PubMed Web of Science ®Google Scholar
• Yu J, Refsum E, Helsingen LM, et al. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: a population-based cohort study. United European Gastroenterol J. 2022;10(2):212–224. doi: 10.1002/ueg2.12204.
   PubMed Web of Science ®Google Scholar
• Erichsen R, Olen O, Sachs MC, et al. Hepatobiliary cancer risk in patients with inflammatory bowel disease: a scandinavian population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2021;30(5):886–894. doi: 10.1158/1055-9965.EPI-20-1241.
   PubMed Web of Science ®Google Scholar
• Sorensen JO, Nielsen OH, Andersson M, et al. Inflammatory bowel disease with primary sclerosing cholangitis: a Danish population-based cohort study 1977-2011. Liver Int. 2018;38(3):532–541. doi: 10.1111/liv.13548.
   PubMed Web of Science ®Google Scholar
• Muller M, Broseus J, Feugier P, et al. Characteristics of lymphoma in patients with inflammatory bowel disease: a systematic review. J Crohns Colitis. 2021;15(5):827–839. doi: 10.1093/ecco-jcc/jjaa193.
   PubMed Web of Science ®Google Scholar
• Lopez A, Mounier M, Bouvier AM, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12(8):1324–1329. doi: 10.1016/j.cgh.2014.02.026.
   PubMed Web of Science ®Google Scholar
• Huang SZ, Liu ZC, Liao WX, et al. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2019;34(3):507–516. doi: 10.1111/jgh.14533.
   PubMed Web of Science ®Google Scholar
• Solitano V, D’Amico F, Correale C, et al. Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. Br Med Bull. 2020;136(1):107–117. doi: 10.1093/bmb/ldaa033.
   PubMed Web of Science ®Google Scholar
• Khan N, Patel D, Trivedi C, et al. Incidence of acute myeloid leukemia and myelodysplastic syndrome in patients With inflammatory bowel disease and the impact of thiopurines on their risk. Am J Gastroenterol. 2021;116(4):741–747. doi: 10.14309/ajg.0000000000001058.
   PubMed Web of Science ®Google Scholar
• Pasternak B, Svanstrom H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177(11):1296–1305. doi: 10.1093/aje/kws375.
   PubMed Web of Science ®Google Scholar
• Statistics Norway. Percentage daily smokers and occasional smokers, by sex and age (per cent) 1973 – 2021; 2022. [accessed 2022 June 1] Available from https://www.ssb.no/en/statbank/table/05307.
   Google Scholar
• Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–1231. doi: 10.1016/j.ejca.2008.10.037.
   PubMed Web of Science ®Google Scholar